BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Nautilus Neurosciences, Inc. 

135 Rte. 202/206

Bedminster  New Jersey  07921  U.S.A.
Phone: 908-203-4600 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Depomed, Inc. (DEPO) BagsCAMBIA® Migraine Med From Nautilus Neurosciences, Inc. For $48.7 Million 12/18/2013 6:58:02 AM    More...
Nautilus Neurosciences, Inc. Announces Co-Promotion Agreement for Lorzone™ 6/12/2013 10:28:59 AM    More...
Eric Liebler, Founder and Former President of Nautilus Neurosciences, Inc., Joins ElectroCore 1/9/2013 7:33:13 AM    More...
Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA(R) for the Acute Treatment of Migraine 3/20/2012 8:53:37 AM    More...
Nautilus Neurosciences, Inc. Announces New Patent Issued 2/1/2012 9:52:06 AM    More...
Nautilus Neurosciences, Inc. Appoints Peter Lankau as Executive Chairman 11/8/2011 8:51:01 AM    More...
Nautilus Neurosciences, Inc. Selects Mission3 OnDemand Virtual Data Room 8/19/2011 9:18:42 AM    More...
Nautilus Neurosciences, Inc. and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA(TM) (diclofenac potassium for oral solution) for the Acute Treatment of Migraine 11/16/2010 6:43:12 AM    More...
Nautilus Neurosciences, Inc.: New Analysis of CAMBIA(TM) Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 10/26/2010 7:13:24 AM    More...
Nautilus Neurosciences, Inc. and Mission Pharmacal Company Announce Exclusive Co-Promotion Agreement for CAMBIA(TM) (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 10/6/2010 6:53:35 AM    More...
12

//-->